Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.74 |
| ▸ | MC4R | P32245 | 3/20 | 0.74 |
| ▸ | MC5R | P33032 | 2/20 | 0.74 |
| ▸ | MC3R | P41968 | 2/20 | 0.74 |
| ▸ | MC1R | Q01726 | 2/20 | 0.74 |
| ▸ | CTSL | P07711 | 3/20 | 0.66 |
| ▸ | CTSS | P25774 | 3/20 | 0.66 |
| ▸ | CTSK | P43235 | 3/20 | 0.66 |
| ▸ | CTSH | P09668 | 1/20 | 0.66 |
| ▸ | GLP1R | P43220 | 4/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.63 |
| ▸ | GCGR | P47871 | 3/20 | 0.62 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Giractide SCHEMBL29387618 | 0.96 | MC4R (0.75) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL18388638 | 0.96 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL29973172 | 0.95 | C5AR1 (0.77) | C5AR1MC4RMC5RMC3RMC1R | |
| Codactide SCHEMBL29409825 | 0.95 | MC4R (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL29358645 | 0.95 | MC4R (0.82) | C5AR1MC4RMC5RMC3RMC1R | |
| Intermedine SCHEMBL20548027 | 0.95 | MC4R (0.82) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL29534172 | 0.95 | MC4R (0.78) | C5AR1MC4RMC5RMC3RMC1R | |
| Intermedine SCHEMBL22076809 | 0.95 | MC4R (0.82) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL30017682 | 0.95 | C5AR1 (0.77) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL29533733 | 0.94 | MC4R (0.78) | C5AR1MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115663926-A | Light storage frequency modulation control method, system, equipment and medium of photovoltaic virtual synchronous machine | 广东能源集团科学技术研究院有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-114414151-A | Synchronous operation type energy metering device with built-in gateway and Internet of things system | 成都秦川物联网科技股份有限公司 | 2022-04-29 | — | — | CN | claimed |
| CN-122094704-A | Formulations for oral administration of active agents comprising a combination of acid-neutralizing polymer and non-polymeric material | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4646217-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | Stellular Bio, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250186558-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| WO-2025046589-A1 | FORMULATIONS COMPRISING A COMBINATION OF ACID-NEUTRALIZING POLYMERIC AND NON-POLYMERIC SUBSTANCES FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025046590-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2025-03-06 | — | — | WO | disclosed |
| US-20250051830-A1 | MEMBRANE-EMBEDDED NANOPORE AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2025-02-13 | — | — | US | disclosed |
| EP-4482507-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | Entera Bio Ltd. (IL) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2023064805-A1 | MEMBRANE-EMBEDDED NANOPORE AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-4149497-A1 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | Platelet Biogenesis, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20230077811-A1 | ACTIVATION OF NEUROPEPTIDE RECEPTORS ON PLASMACYTOID DENDRITIC CELLS TO TREAT OR PREVENT OCULAR DISEASES ASSOCIATED WITH NEOVASCULARIZATION AND INFLAMMATION | TRUSTEES OF TUFTS COLLEGE | 2023-03-16 | — | — | US | disclosed |
| EP-4125947-A1 | NOVEL ANUCLEATED CELLS FOR THE TREATMENT OF DISEASES | Platelet Biogenesis, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | C5AR1 2999/4885MC4R 2077/4885MC5R 2679/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | C5AR1 3213/4885MC4R 1888/4885MC5R 2483/4885 |
| US-20250186558-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ASAH2, SLC10A2, FABP2 | C5AR1 2220/4885MC4R 1851/4885MC5R 1480/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | C5AR1 3213/4885MC4R 1888/4885MC5R 2483/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | C5AR1 4521/4885MC4R 2181/4885MC5R 2290/4885 |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | C5AR1 1839/4885MC4R 746/4885MC5R 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.